Elanco Animal Health Incorporated (ELAN)Healthcare | Drug Manufacturers - Specialty & Generic | Indianapolis, United States | NYSE
22.61 USD
-1.07
(-4.519%) ⇩
(April 21, 2026, 4 p.m.
EDT)
After hours: 22.90 +0.29 (1.283%) ⇧ (April 21, 2026, 4:25 p.m. EDT) Short-term: ★★★☆☆ | Long-term: ★★★☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 19, 2026, 12:13 a.m. EDT
Elanco (ELAN) is a classic 'hold' for income accounts (yield is non-existent) and a contrarian wedge for long-term investors given its near-break-even fundamentals and high beta (1.88). However, the intrinsically overvalued stance according to GF Value and the ~49% spike in short interest implies that speculators are waiting for a dislocation. While analyst consensus is a 'Buy' with a ~$23 target price, the short-term trend model predicts a slight decline, making it a weak buy in the immediate term despite solid long-term growth potential in once-only animal health. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.033710 |
| AutoETS | 0.033712 |
| AutoTheta | 0.037460 |
| MSTL | 0.039978 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 51% |
| H-stat | 3.67 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.638 |
| Excess Kurtosis | -0.47 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 67.894 |
| Revenue per Share | 9.498 |
| Market Cap | 11,290,969,088 |
| Forward P/E | 19.35 |
| Beta | 1.88 |
| Profit Margins | -4.92% |
| Website | https://www.elanco.com |
As of April 19, 2026, 12:13 a.m. EDT: Options flow shows a distinct bullish bias in implied positioning. Call Open Interest (OI) is heavily skewed Out-of-The-Money (OTM) at the 28.0 strike across multiple expirations, while Put OI is concentrated In-The-Money (ITM) around strikes 19.0 and 20.0, suggesting protection buying at lower levels or a 'long' options gamma risk profile. Volatility (IV) is not significantly elevated relative to spot price, indicating speculators are comfortable with current levels rather than demanding a large discount. The short-term predictive model predicts a -1.18% move with high statistical significance (low Ljung-Box p-value), suggesting mean-reversion is the dominant short-term driver rather than momentum.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.663667 |
| Address1 | 450 Elanco Circle |
| All Time High | 37.61 |
| All Time Low | 7.88 |
| Ask | 22.65 |
| Ask Size | 300 |
| Audit Risk | 9 |
| Average Analyst Rating | 1.5 - Buy |
| Average Daily Volume10 Day | 3,957,860 |
| Average Daily Volume3 Month | 4,908,434 |
| Average Volume | 4,908,434 |
| Average Volume10Days | 3,957,860 |
| Beta | 1.877 |
| Bid | 22.47 |
| Bid Size | 200 |
| Board Risk | 2 |
| Book Value | 13.174 |
| City | Indianapolis |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 22.61 |
| Current Ratio | 2.165 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 23.85 |
| Day Low | 22.605 |
| Debt To Equity | 67.894 |
| Earnings Call Timestamp End | 1,778,068,800 |
| Earnings Call Timestamp Start | 1,778,068,800 |
| Earnings Timestamp | 1,778,070,600 |
| Earnings Timestamp End | 1,778,070,600 |
| Earnings Timestamp Start | 1,778,070,600 |
| Ebitda | 908,000,000 |
| Ebitda Margins | 0.19258 |
| Enterprise To Ebitda | 17.261 |
| Enterprise To Revenue | 3.324 |
| Enterprise Value | 15,672,940,544 |
| Eps Current Year | 1.0343 |
| Eps Forward | 1.16847 |
| Eps Trailing Twelve Months | -0.47 |
| Esg Populated | 0 |
| Exchange | NYQ |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 24.343 |
| Fifty Day Average Change | -1.7329998 |
| Fifty Day Average Change Percent | -0.071190886 |
| Fifty Two Week Change Percent | 166.3667 |
| Fifty Two Week High | 27.72 |
| Fifty Two Week High Change | -5.1099987 |
| Fifty Two Week High Change Percent | -0.1843434 |
| Fifty Two Week Low | 8.59 |
| Fifty Two Week Low Change | 14.02 |
| Fifty Two Week Low Change Percent | 1.6321304 |
| Fifty Two Week Range | 8.59 - 27.72 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,537,450,200,000 |
| Float Shares | 492,678,649 |
| Forward Eps | 1.16847 |
| Forward P E | 19.35009 |
| Free Cashflow | 559,750,016 |
| Full Exchange Name | NYSE |
| Full Time Employees | 9,400 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.54995 |
| Gross Profits | 2,592,999,936 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.01189 |
| Held Percent Institutions | 1.09401 |
| Implied Shares Outstanding | 499,379,439 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Industry Disp | Drug Manufacturers - Specialty & Generic |
| Industry Key | drug-manufacturers-specialty-generic |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. The company offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio Family, Interceptor Plus, Drontal family, and Drontal Plus; vaccines portfolio that provides differentiated prevention coverage for a number of important pet health risks; and therapeutics portfolio for the treatment of pain, otitis, cardiovascular, and dermatology indications, as well as osteoarthritis for dogs and cats under the Galliprant trademark. It also provides farm animal products that help farmers improve animal health and wellbeing, and raise livestock, such as cattle, swine, and poultry. In addition, the company offers medicated feed additives, injectable antibiotics, vaccines, insecticides and enzymes, and others under the Rumensin, Baytril, and Experior trademarks for cattle; and under the Maxiban and Monteban trademarks for the control and prevention of intestinal disease in poultry. Further, it offers other pet health products for cats and dogs under the Atopica, Milbemax, Onsior, and Tru Family trademarks; and other farm animal products for poultry, cattle, and swine under the AviPro, Catosal, Denagard, Hemicell, Pulmotil, and Surmax tradmarks. The company sells its products to third-party distributors and independent retailers; and directly to farm animal producers and veterinarians. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Indianapolis, Indiana. |
| Long Name | Elanco Animal Health Incorporated |
| Market | us_market |
| Market Cap | 11,290,969,088 |
| Market State | POST |
| Max Age | 86,400 |
| Message Board Id | finmb_576158911 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -232,000,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 11,825,305,115 |
| Number Of Analyst Opinions | 14 |
| Open | 23.65 |
| Operating Cashflow | 560,000,000 |
| Operating Margins | 0.02273 |
| Overall Risk | 4 |
| Payout Ratio | 0.0 |
| Peg Ratio | 3.99 |
| Phone | 877 352 6261 |
| Post Market Change | 0.289999 |
| Post Market Change Percent | 1.2826139 |
| Post Market Price | 22.9 |
| Post Market Time | 1,776,803,100 |
| Previous Close | 23.68 |
| Price Eps Current Year | 21.860197 |
| Price Hint | 2 |
| Price To Book | 1.7162594 |
| Price To Sales Trailing12 Months | 2.3946912 |
| Profit Margins | -0.049200002 |
| Quick Ratio | 1.001 |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 1.52941 |
| Region | US |
| Regular Market Change | -1.07 |
| Regular Market Change Percent | -4.51858 |
| Regular Market Day High | 23.85 |
| Regular Market Day Low | 22.605 |
| Regular Market Day Range | 22.605 - 23.85 |
| Regular Market Open | 23.65 |
| Regular Market Previous Close | 23.68 |
| Regular Market Price | 22.61 |
| Regular Market Time | 1,776,801,602 |
| Regular Market Volume | 3,912,447 |
| Return On Assets | 0.0124699995 |
| Return On Equity | -0.0367 |
| Revenue Growth | 0.122 |
| Revenue Per Share | 9.498 |
| Sand P52 Week Change | 0.34445214 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 2 |
| Shares Outstanding | 499,379,439 |
| Shares Percent Shares Out | 0.0511 |
| Shares Short | 25,535,642 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 15,072,733 |
| Short Name | Elanco Animal Health Incorporat |
| Short Percent Of Float | 0.0813 |
| Short Ratio | 4.53 |
| Source Interval | 15 |
| State | IN |
| Symbol | ELAN |
| Target High Price | 32.0 |
| Target Low Price | 20.0 |
| Target Mean Price | 28.78571 |
| Target Median Price | 30.0 |
| Total Cash | 545,000,000 |
| Total Cash Per Share | 1.096 |
| Total Debt | 4,445,000,192 |
| Total Revenue | 4,714,999,808 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.47 |
| Trailing Peg Ratio | 3.9865 |
| Triggerable | 1 |
| Two Hundred Day Average | 21.15335 |
| Two Hundred Day Average Change | 1.4566498 |
| Two Hundred Day Average Change Percent | 0.06886142 |
| Type Disp | Equity |
| Volume | 3,912,447 |
| Website | https://www.elanco.com |
| Zip | 46,221 |